Latest "Oncology Network" News Stories

03:25 EDT 22nd March 2019 | BioPortfolio

Here are the most relevant search results for "Oncology Network" found in our extensive news archives from over 250 global news sources.

More Information about Oncology Network on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Oncology Network for you to read. Along with our medical data and news we also list Oncology Network Clinical Trials, which are updated daily. BioPortfolio also has a large database of Oncology Network Companies for you to search.

Showing "Oncology Network" News Articles 1–25 of 8,400+


Women4Oncology: Professional equity in oncology

In 2000, the European Society for Medical Oncology had a membership in the thousands, but only 20% of them were women. Today that figure has nearly doubled. This changing professional population has access to, and encouragement from, a supportive network...

OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi in Combination with Nivolumab in Pancreatic Cancer

The Phase 2 clinical trial of Tedopi in pancreatic cancer will be sponsored by the oncology group GERCOR The study will explore Tedopi's potential in an additional oncology indication Regulatory N...

The PGC-1/ERR network and its role in precision oncology

NCCN Awarded $2 Million in Research Funding from Taiho Oncology to Study Trifluridine and ...

PLYMOUTH MEETING, Pa., Oct. 22, 2018 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces plans to develop a program to Read more...

BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences

BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces it has been selected to present a poster at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, held February 28–March 2, 2019, in San Francisco, California. The post BriaCell to ...

Alphamab Oncology brings in $100mm via Series A

Jiangsu Alphamab Biopharmaceuticals Co. Ltd. (Alphamab Oncology) raised over $100mm in its Series A financing to Advantech Ca...

Merck and IMV Form Oncology Collaboration

For some, Merck’s cancer drug Keytruda may seem like one of the most developed drugs with multiple US Food and Drug Administration (FDA) approvals. However, it’s also proving to be a popular choice for partnerships. The post Merck and IMV Form Oncology Collaboration appeared first on Investing News Network.

Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on Biomark HD

Fluidigm (NASDAQ:FLDM) and GenomOncology today announced an expanded Immuno-Oncology Gene Expression Workflow to accelerate the development of checkpoint immunotherapies and the identification of potential predictive biomarker signatures for therapeutic response. As quoted in the press release: The integrated solution for immuno-oncology research spans RNA extraction through data analysis with an ...

Guest Article: Is your network optimized for EMRs and large document traffic?

In the rush to install EMRs tech folks often forget that you need to make sure that your network can handle the (usually significant) load that medical records automation will add to your network infrastructure. I invited Jon Mills of of Plixer International, Inc., a Maine-based software development company that specializes in network traffic analysis using NetFlow and other flow-based monitoring ...

Is your Health IT Network NSA-secure?

The NSA’s unclassified 60 Minute Network Security Guide is a great way to check that your network security is up to par with the nation’s pre-eminent spy agency’s guidelines. Check it out and see if your network measures up — leave some comments here to tell us what you think about the guidance provided.

Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001

Gritstone Oncology (Nasdaq:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GRANITE-001 for the treatment of colorectal cancer. As quoted in the press release: GRANITE-001 is a personalized immunotherapy contain...

Biotech Trends 2018: Immuno-Oncology Disappoints

2018 marked another critical year of growth for the biotech market, influenced by multiple trends in the sector. The post Biotech Trends 2018: Immuno-Oncology Disappoints appeared first on Investing News Network.

The US Oncology Network Announces Top-Tier MIPS Results

Affiliated practices to benefit from high positive payment adjustment The US Oncology Network (The Network) today announced results of the 2017 Merit-based Incentive Payment System (MIPS) for its affiliated practices. Based on the successful implementation of quality improvement, adoption and performance in the first year of MIPS, practices in The Netw...

OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi® in Combination with Nivolumab in Pancreatic Cancer

The Phase 2 clinical trial of Tedopi® in pancreatic cancer will be sponsored by the oncology group GERCOR The study will explore Tedopi®’s potential in an additional oncology indication NANTES, France, Oct. 10, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced the submission of an Investigational New Drug (IND) application to initiate a Ph...

Ockham Oncology’s CSO highlights global strength of fully integrated company.

Ockham Oncology’s Chief Scientific Officer Clare Wareing, PhD recounts the companies history and emphasizes complementary strengths that add value following the combination of Ockham Oncology and Nexus Oncology.

OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Combination with Opdivo® (nivolumab) in Pancreatic Cancer

The trial, sponsored and conducted by oncology group GERCOR, will be supported by Bristol-Myers Squibb and OSE ImmunotherapeuticsPancreatic cancer is an indication with significant unmet need and represents an important new opportunity for Tedopi® clinical developmentOpening of Phase 2 trial sites scheduled for early 2019 NANTES, France, Nov. 20, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeuti...

Network Atlas Launches Map of Global Internet Infrastructure

IRVINE, Calif., Nov. 1, 2018 /PRNewswire/ -- A new service will radically amplify the ability of network professionals around the world to identify potential network Read more...

Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets

Ziopharm Oncology (Nasdaq:ZIOP) today responded to the recent decline in the Company’s stock price, which accelerated greatly on December 26, 2018, the same day that the broader market and all indexes were up significantly. As quoted in the press release: “Our stock price is significantly down of late, and we want to assure the market … Continued The post Ziopharm Oncology Responds to Re...

Value Pioneer Trades Independence for Reach

To implement its value-based models of care on a broader scale, Consultants in Medical Oncology and Hematology of Philadelphia has decided to join a large network of practices.

Axel Hoos, GSK: Focusing on immuno-oncology and cancer epigenetics

GSK has had a recent change in Oncology after recently divesting their marketed oncology products to Novartis whilst retaining their R&D pipeline. During BIO 2015, Axel Hoos, VP Oncology R&D at GSK explained to Fintan Walton, CEO of PharmaVentures what these changes will mean and how they are now focussing on two areas of cutting edge science.

One Network Enterprises Recognized for Outstanding Corporate Culture-Company Named a Best ...

DALLAS, Jan. 8, 2019 /PRNewswire/ -- One Network Enterprises, the global provider of multiparty digital network platform and services, today announced that it was certified Read more...

Syapse to Utilize NCCN Biomarkers Compendium for More Personalized Care

New partnership between National Comprehensive Cancer Network and Syapse will augment health information technology around cancer care. The National Comprehensive Cancer Network(NCCN) announced a new agreement with Syapse, a precision medicine company, to expand the use of best practices in precision medicine when treating people with cancer. Syapse delivers solutions for scaling enterprise precis...

Oasmia Pharmaceutical announces new agreement with Baxter Oncology

Oasmia Pharmaceutical (Nasdaq:OASM) today announce that the company has signed a new five-year contract with Baxter BioPharma Solutions for global commercial manufacturing of Apealea. Technology and know-how are already transferred to Baxter and manufacturing is planned to commence within a short period of time. As quoted in the press release: Apealea will be manufactured at … Continued The ...

GSK indicates oncology intent with €3.7bn Merck deal

GSK moves to rebuild its oncology pipeline by partnering with Merck KGaA on an immuno-oncology drug candidate.

US FDA approves Catalent’s collaborative oncology treatment

Oncology drug Copiktra was developed during a multi-year collaboration between Catalent Pharma and Verastem Oncology.

Quick Search


News Quicklinks